key: cord-0937114-uownyy5k authors: Rakib, Ahmed; Sami, Saad Ahmed; Mimi, Nusrat Jahan; Chowdhury, Md. Mustafiz; Eva, Taslima Akter; Nainu, Firzan; Paul, Arkajyoti; Shahriar, Asif; Tareq, Abu Montakim; Emon, Nazim Uddin; Chakraborty, Sajal; Shil, Sagar; Mily, Sabrina Jahan; Ben Hadda, Taibi; Almalki, Faisal A.; Emran, Talha Bin title: Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein date: 2020-08-13 journal: Comput Biol Med DOI: 10.1016/j.compbiomed.2020.103967 sha: 1769613748e203c9347447b9ef2830336f0ec47f doc_id: 937114 cord_uid: uownyy5k AIMS: With a large number of fatalities, coronavirus disease-2019 (COVID-19) has greatly affected human health worldwide. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes COVID-19. The World Health Organization has declared a global pandemic of this contagious disease. Researchers across the world are collaborating in a quest for remedies to combat this deadly virus. It has recently been demonstrated that the spike glycoprotein (SGP) of SARS-CoV-2 is the mediator by which the virus enters host cells. MAIN METHODS: Our group comprehensibly analyzed the SGP of SARS-CoV-2 through multiple sequence analysis and a phylogenetic analysis. We predicted the strongest immunogenic epitopes of the SGP for both B cells and T cells. KEY FINDINGS: We focused on predicting peptides that would bind major histocompatibility complex class I. Two optimal epitopes were identified, WTAGAAAYY and GAAAYYVGY. They interact with the HLA-B*15:01 allele, which was further validated by molecular docking simulation. This study also found that the selected epitopes are able to be recognized in a large percentage of the world's population. Furthermore, we predicted CD4(+) T-cell epitopes and B-cell epitopes. SIGNIFICANCE: Our study provides a strong basis for designing vaccine candidates against SARS-CoV-2. However, laboratory work is required to validate our theoretical results, which would lay the foundation for the appropriate vaccine manufacturing and testing processes. cases has continued to escalate exponentially and is considered to be the largest outbreak of 62 atypical pneumonia in recent times. 63 Tyrell and Bynoe first described the coronaviruses in 1966 [5] . Coronaviruses are 64 pleomorphic or spherical particles with a positive single-strand RNA (+ssRNA). These viruses glycoprotein does not occur in other coronaviruses [17] . Among the structural proteins, the S 108 protein is a multifunctional molecular machine; a recent study by Walls et al clarified the 109 structure, function, and immunogenicity of the S protein [18] . The SGP can attach to a specific 110 human host receptor, ACE2, on the surface of human cells. This receptor binding process 111 mediates the entry of viral particles into the host cells with the aid of its protease, which cleaves 112 the spike protein into the S1 and S2 subunits [19, 20] . The SGP binds to ACE2, located on the 113 surface of host cells, through the receptor binding domain (RBD), which is part of the S1 114 subunit. Subsequently, the viral and host membranes are fused by the S2 subunit. The viral 115 genome RNA is released into the cytoplasm after this membrane fusion. Hence, developing 116 neutralizing antibodies against the RBD of SARS-CoV-2 SGP might be an ideal vaccine 117 strategy. 118 The identification of B-cell and T-cell epitopes for spike glycoproteins is critical for 119 developing an effective vaccine. Although humans normally demonstrate an antibody response 120 against viruses, only neutralizing antibodies can completely block the entry of viruses into 121 human cells [21] . The location of antibody binding sites on a viral protein strongly affects the 122 body's ability to produce neutralizing antibodies [22] . It is crucial to ascertain whether SARS- 123 CoV-2 has any potential antibody binding sites (B-cell epitopes) in the RBD region, because this 124 is the area where the virus interacts with its known human receptor, ACE2.. 125 Apart from neutralizing antibodies, the human body also relies on cytotoxic CD8 + T cells 126 and helper CD4 + T cells to eliminate viruses from the body. The presentation of a peptide will 127 allow a B cell to receive stimulation from a helper T cell and become a plasma cell so that it can 128 generate antibodies. T-cell epitopes in connection with MHC proteins are presented to T cells to 129 elicit an antiviral T-cell response. Cytotoxic T cells recognize peptides that are received from the recent years, as they can target conserved regions of the virus to elicit T cell responses and 137 provide long-term protection against different strains of viruses [24] . 138 Currently, no clinically proven vaccine grants immunity to SARS-CoV-2 infection. 139 Researchers have examined different repurposed compounds from other viral infections to treat 140 COVID-19, but the treatment benefit derived has been marginal or nonexistent in most cases 141 [25] . However, with the rapid expansion of research in this area, it is hoped that a vaccine against designing an epitope-based peptide vaccine against SARS-CoV-2 infection using in silico 168 methods by investigating its SGP. We targeted the epitopes of the SGP because they reportedly 169 induce a longer-lasting immune response against SARS coronavirus [34] . We assessed the 170 associated MHC alleles for the identified epitopes to determine those epitopes that would 171 maximize population coverage across the world. As a result, using different computational tools, 172 we designed an epitope-based peptide vaccine that would theoretically target the SARS-CoV-2 173 SGP with the expectation of subsequent wet laboratory validation. The SARS-CoV-2 SGP sequence was extracted from the UniProt database (UniProt entry: 179 P0DTC2) in FASTA format [35] . The features, function, structure, and evaluation of the 180 sequence were mainly based on the process of sequence analysis, which subjects DNA, RNA, or 181 peptide sequences to a wide range of analytical methods. We screened homologous sequences 182 from the BLASTp database and selected those sequences that were most similar to that of SARS- CoV-2 SGP. We also performed multiple sequence alignment (MSA) using the ClustalW web 184 server with default settings, and a phylogenetic tree was established using the Clustal tree format 187 To determine the potent antigenic protein of the SARS-CoV-2 SGP, we used the online 188 server VaxiJen v2.0, with a default threshold value [37] . All the antigenic proteins of SARS- CoV-2 SGP with their respective scores were obtained and then sorted in Notepad++. determine the overall scores and translated into sensitivity/specificity. Based on this overall 199 score, the ten best peptides (epitopes) were selected for further evaluation. 208 The degree of similarity between the epitope and the target (i.e. given) sequence is 209 elucidated by epitope conservancy. This property of an epitope indicates its availability in a 210 range of different strains. The web-based tool from IEDB analysis resources was used to analyze 211 the epitope conservancy [41] . Immunogenicity prediction can infer the degree to which a 212 particular epitope will produce an immunogenic response. The T-cell class I pMHC 242 To predict MHC class II potential epitopes, we utilized the MHC II prediction tools from 261 The protein sequence of the SARS-CoV-2 SGP was retrieved from the UniProt database 262 and then BLASTp was performed. From the many identified homologs, we selected only 17 that 263 had greater than 60% sequence identity. MSA was performed (Supplementary Data 1) and a 264 phylogenetic tree was constructed ( Figure S1 ). The MSA and phylogenetic results indicated that 265 the protein sequences have a close relationship. 296 On the basis of the highest combinatorial score and MHC class I binding, 23 epitopes were 297 predicted by NetCTL 1.2 from the given protein sequence. The antigenicity of each selected 298 peptide was predicted by VaxiJen v2.0, and we found that ten epitopes were antigenic (Table 299 S1 ). The MHC-I binding prediction tool from the IEDB server was used to assess affinity; this 300 tool is based on the stabilized matrix method. We chose the MHC-I alleles for which the epitopes (Table 1 ). In addition, two other epitopes, namely GAAAYYVGY and STQDLFLPF, interacted 310 with MHC I alleles. The former interacted with five HLAs and the latter interacted with nine. (Table 1) . Furthermore, all the predicted epitopes had a maximum identity for 316 conservancy, and 100% maximum identity was found (Table 1) . Therefore, we selected the 317 J o u r n a l P r e -p r o o f aforementioned three epitopes for further analysis. In addition, MHC-NP found that these 318 epitopes would naturally bind to the MHC class I alleles (Table S2) . 319 By concentrating on potential MHC class I peptide epitopes, we predicted not only T-cell 320 but also B-cell epitopes. Both of these epitope types are capable of showing immune responses in 321 several ways. Many criteria must be met when identifying a protein sequence-based epitope as a 322 potential vaccine candidate, whereby allergenicity is regarded as one of the most important 323 factors. We input the SARS-CoV-2 SGP sequence into the VaxiJen server and predicted the 324 antigenicity of the protein sequence. Ten potent epitopes were predicted by the NetCTL 1.2 325 server, and the epitopes were further used in the progressive analysis that also showed MHC Additionally, the aforementioned epitopes also interacted with HLA-B*15:01, and epitope 332 WTAGAAAYY showed the highest affinity for it. In addition, the epitope conservancy was 333 predicted by the IEDB conservancy analysis tool, and all of our predicted epitopes had a 334 maximum identity of 100%. Hence, these three epitopes were selected for further analysis. 336 The AllerTop server assesses the allergic reactions caused by a vaccine candidate in an 337 individual that might be harmful or life-threatening. The allergenicity of the selected epitopes 338 was calculated using the AllerTop tool, and they were predicted as probable non-allergens. Allergenicity is regarded as a notable obstacle during vaccine development. CD4 + T cells 340 are the primary actors responsible for provoking an allergic reaction, but immunoglobulin E and 341 type 2 T helper cells can also stimulate allergic reactions [67] . We evaluated the allergenicity 342 using AllerTop 2.0. This tool is well-known for its high sensitivity to identify new allergens in 343 relation to known allergens [43] . AllerTop predicted our selected epitopes to be non-allergenic. The docking experiments showed that the epitope WTAGAAAYY interacted with HLA-354 B*15:01 with the highest binding affinity, which was calculated as -10.0 kcal/mol; the binding 355 affinity of GAAAYYVGY was almost equal to that of GAAAYYVGY (-9.4 kcal/mol). However, 356 the binding affinity of the epitope STQDLFLPF was found to be only -8.3 kcal/mol (Table 2) . these two epitopes were able to interact with the allele through H-bonds and hydrophobic (pi-pi 375 stacking, pi-alkyl) interactions, and attractive charges also contributed to binding in the case of GAAAYYVGY. Conversely, the epitope STQDLFLPF had a less negative docking score; hence, 377 its binding interaction was weaker in comparison with the other two epitopes. 379 In this experiment, potential CD4 + T-cell peptide epitopes were identified by the MHC 380 class II prediction tool from the IEDB website, which provided 56 core epitopes for the selected Table 3 . 385 Vaccination strategies that only depend on CD8 + T-cell immunity might be inadequate, 410 We first analyzed the individual epitopes that interacted with MHC class I alleles. West 411 Africa had the highest coverage region for epitopes WTAGAAAYY and STQDLFLPF, at 412 76.33% and 58.93%, respectively (Table S3) . South Asia had the highest coverage region for the 413 epitope GAAAYYVGY, at 32.67% (Table S3) Figures S2-S5 . 420 We next conducted a population coverage analysis for MHC class II alleles. As in the 421 MHC class I analysis, we first individually predicted the population coverage for the MHC II 422 alleles to find the maximum MHC II interaction. The core epitope LALHRSYLT showed the 423 maximum coverage, which was 34.63% for the North American region (Table S4) Africa. Surprisingly, of the regions where the most cases of the infection were reported (namely, 440 Europe and North America), the coverage was greater than 65%; thus, the coverage of Europe 449 In the current study, linear B-cell epitopes were identified by utilizing an amino acid-450 based method. The BepiPred linear epitope prediction tool was applied, which is regarded as the best 452 method for predicting linear B-cell epitopes. This tool uses a hidden Markov model. A total of 68 453 linear epitopes were predicted by BepiPred. By selecting only those with lengths ≥7 amino acid 454 residues, 19 epitopes were finally included for further analysis ( Table 5) (Table S5 ). The region of residues 499-505 had a score of 1.257, and the 1140-1146 459 region had a score of 1.057; these were all greater than the average score ( Figure 5) . 460 The Emini surface accessibility prediction method was also employed in this study. The Pseudomonas aeruginosa in mice [81] . Synthetic peptides that contain linear B-cell epitopes are 487 pivotal for producing antibodies against a specific protein; these antibodies can be used in 488 various applications, such as in diagnostic tools or screening assays [82] . Importantly, B-cell (Table S6 ) [77] . In addition, the Grifoni study found that the predicted epitopes had a sequence 498 identity greater than 65% [77]. The predicted B-cell epitopes were also in agreement with 499 another previous study that had predicted several SARS-CoV-2 SGP B-cell epitopes (Table S6 ) 500 [83]. Our study is not exhaustive, and in silico work has several pros and cons. The vaccine 502 development process is tedious, and it can take years to develop a vaccine for use in humans, 503 especially when the technologies are new and have not been extensively used before. Although 504 institutes such as Curevac, Inovio, and Applied DNA Sciences are working on vaccines focusing 505 on the SGP of SARS-CoV-2, it is not possible to predict how long it will take to obtain a 506 successful vaccine. Realistically, an animal model is a prerequisite for testing the protectiveness 507 of a vaccine, but developing an animal model for SARS-CoV-2 has been difficult. Vaccines also 508 must be tested for toxicity in various animals, for example, rabbits, which typically takes several 509 months to complete. Human vaccines must be produced in accordance with current good 510 manufacturing practices (cGMPs), which requires trained personnel, exclusive facilities, 511 appropriate documentation, and quality raw materials. As a result, vaccine candidates that are in 512 the preclinical phase might require specialized processes that need to be developed from scratch. Realistically, it will require more than 1 year to license any vaccine for SARS-CoV-2. information is transferred to both T cells and B cells. Here, utilizing in silico simulations, our 522 predicted epitopes were able to interact with CD8 + cells when the epitopes were presented as 523 antigens. However, the present study is only a preliminary approach for predicting an epitope-524 based vaccine against SARS-CoV-2. We hope that these predicted epitopes will lay the 525 foundation for the further experimental design of vaccine candidates against SARS-CoV-2. The raw data supporting the conclusions of this manuscript will be made available by the 534 authors, without undue reservation, to any qualified researcher. Table Legends 788 Table 1 . The potential CD8 + T-cell epitopes along with their interacting MHC class I alleles and 789 total processing score, epitopes conservancy hits and pMHC-I immunogenicity score. Table S1 . Antigenicity prediction of selected epitopes using VaxiJen 2.0 server. 820 Table S2 . MHC-NP probability score for the selected epitopes. shown as red ball and stick, the interacting B chain residues were shown in blue ball and sick, conventional hydrogen bonds were 878 shown as green line, pi-pi/pi-alkyl stacking were shown as pink lines, unfavorable bumps were shown as red lines. First case of 2019 novel coronavirus in the United States Preliminary identification of potential vaccine 603 targets for the COVID-19 Coronavirus (SARS-CoV-2) Based Complete genome characterisation of a novel coronavirus associated 607 with severe human respiratory disease in Wuhan Structure, 609 function, and antigenicity of the SARS-CoV-2 spike glycoprotein Structural insights into coronavirus entry Receptor-binding domain as a target for developing 613 SARS vaccines Immunology of avian influenza virus: a review Sesterhenn, others, Tailored immunogens direct affinity maturation toward 618 HIV neutralizing antibodies CD4+ T cell epitope discovery and rational 620 vaccine design Revival of the identification of cytotoxic T-622 lymphocyte epitopes for immunological diagnosis, therapy and vaccine development 625 others, A trial of lopinavir--ritonavir in adults hospitalized with severe Covid-19 628 others, Development of an inactivated vaccine candidate for SARS-CoV-2 Development of an inactivated vaccine candidate, BBIBP-CorV, with 632 potent protection against SARS-CoV-2 Progress and prospects on vaccine 634 development against SARS-CoV-2, Vaccines Vaccinomics and a new paradigm for the development of preventive vaccines against viral 637 infections Bin Emran, others, Epitope-based Immunoinformatics 640 Approach on Nucleocapsid Protein of Severe Acute Respiratory Syndrome-Coronavirus-641 2 Design of multi-643 epitope vaccine candidate against SARS-CoV-2: a in-silico study COVID-19 coronavirus vaccine design using 646 reverse vaccinology and machine learning In silico identification of vaccine targets for 2019-nCoV Antigenicity and 650 immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in 651 CHO cells UniProt: the universal protein knowledgebase VaxiJen: a server for prediction of protective antigens, 657 tumour antigens and subunit vaccines Computational 659 MHC-I epitope predictor identifies 95% of experimentally mapped HIV-1 clade A and D 660 epitopes in a Ugandan cohort The immune epitope database (IEDB): 2018 update MHC-NP: 665 predicting peptides naturally processed by the MHC Development of an epitope 668 conservancy analysis tool to facilitate the design of epitope-based diagnostics and 669 vaccines A consensus epitope prediction approach identifies the breadth of murine T CD8+-672 cell responses to vaccinia virus AllerTOP-a server for in silico prediction of 674 allergens PEP-FOLD: an online resource for de novo 676 peptide structure prediction SWISS-MODEL and the Swiss-Pdb Viewer: an environment for 678 comparative protein modeling PyRx-python prescription v. 0.8 Open Babel: An open chemical toolbox AutoDock Vina: Improving the speed and accuracy of docking with 683 a new scoring function, efficient optimization, and multithreading Reliable prediction of T-cell epitopes using neural networks with novel 687 sequence representations Functional 689 classification of class II human leukocyte antigen (HLA) molecules reveals seven 690 different supertypes and a surprising degree of repertoire sharing across supertypes Predicting 693 population coverage of T-cell epitope-based diagnostics and vaccines Induction of hepatitis A virus-neutralizing 696 antibody by a virus-specific synthetic peptide A semi-empirical method for prediction of antigenic 698 determinants on protein antigens Prediction of chain flexibility in proteins Improved method for predicting linear B-cell 702 epitopes Empirical predictions of protein conformation Bonilla-Aldana, others, A vaccine is not too far for COVID-19 Insights into cross-species evolution of novel human 709 coronavirus 2019-nCoV and defining immune determinants for vaccine development Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for 713 developing subunit vaccine A truncated receptor-binding domain of MERS-CoV spike protein potently 716 inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines Design of a Multiepitope-Based Peptide Vaccine against the E 720 Protein of Human COVID-19: An Immunoinformatics Approach Comparison of open-source reverse 723 vaccinology programs for bacterial vaccine antigen discovery Role of changes in SARS-CoV-2 726 spike protein in the interaction with the human ACE2 receptor: An in silico analysis An in-729 silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using 730 NSP15 and fusion spike glycoprotein as targets Core structure of gp41 from the HIV envelope 732 glycoprotein Atomic structure of 734 the ectodomain from HIV-1 gp41 T-cell co-stimulatory 736 molecules: their role in allergic immune reactions In vivo 741 and in vitro pharmacological activities of Tacca integrifolia rhizome and investigation of 742 possible lead compounds against breast cancer through in silico approaches CD8 T cell memory development: CD4 T cell 745 help is appreciated Helping the CD8+ T-cell response CD4 T cells are required for CD8 T cell survival during both primary and memory recall responses Mutation analysis of the 751 cross-reactive epitopes of Japanese encephalitis virus envelope glycoprotein PREDIVAC: CD4+ T-cell epitope prediction 754 for vaccine design that covers 95% of HLA class II DR protein diversity In silico predicted mycobacterial epitope 758 elicits in vitro T-cell responses From ZikV genome to vaccine: in 760 silico approach for the epitope-based peptide vaccine against Zika virus envelope 761 glycoprotein A sequence 763 homology and bioinformatic approach can predict candidate targets for immune responses 764 to SARS-CoV-2 A computational assay to design an epitope-based Peptide 766 vaccine against Saint Louis encephalitis virus A totally synthetic polyoxime malaria 770 vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits 771 immune responses in volunteers of diverse HLA types In-silico design of a multi-epitope 774 vaccine candidate against onchocerciasis and related filarial diseases Ability of synthetic peptides representing epitopes of outer 777 membrane protein F of Pseudomonas aeruginosa to afford protection against P. aeruginosa 778 infection in a murine acute pneumonia model The diagnostic properties of rheumatoid arthritis 781 antibodies recognizing a cyclic citrullinated peptide Development of epitope-based peptide vaccine against novel coronavirus 785 2019 (SARS-COV-2): Immunoinformatics approach